The Filing Desk

Akebia Therapeutics

AKBA · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

AKBA · Last close · November 19, 2026
$0.42
Value Akebia Therapeutics yourself

Akebia Therapeutics' revenue rose 47.5% to $236 million in fiscal 2025. Its operating margin was 9.9%, up from −31.5% a year earlier. Free cash flow was $68 million. The diluted share count rose 21.9%.

AKEBIA THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001517022-26-000020 Updated
Revenue
$236M
47.5%
Operating margin
9.9%
41.5 pts
Net income
−$5M
 
Free cash flow
$68M
 
Return on equity
—
 
Market cap
$117M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Akebia Therapeutics does

Akebia Therapeutics is a drug company focused on kidney disease. It sells two products in the United States. Vafseo is a pill, approved by the FDA in March 2024, that treats anemia caused by chronic kidney disease in adults who have been on dialysis for at least three months. Auryxia is a pill that controls phosphorus levels in adults on dialysis and treats iron deficiency anemia in adults with kidney disease who are not on dialysis.

Akebia earns money from sales of both products. Vafseo reached the market in January 2025, and Akebia says it has supply agreements with dialysis organizations that care for nearly 100% of dialysis patients in the U.S. Partners sell Vafseo in some countries outside the United States, and approved use covers adults in 37 countries.

The company also has mid-stage programs for rare kidney diseases and earlier-stage programs, which are not yet approved and need further trials.

Its biggest risks, as it describes them

  • Its business depends heavily on selling Auryxia and Vafseo.
  • It has lost money since it began and may need more financing, which could dilute owners or restrict it.
  • Its loan with BlackRock and its royalty deal with HealthCare Royalty Partners carry strict terms.
  • Insurers or government programs may not cover or pay enough for its medicines.
  • It may not find, develop or sell additional products.
From Akebia Therapeutics's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Akebia Therapeutics lost money in fiscal 2025: a net loss of $5 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments150904352185
Debt incl. finance leases9866353948
Net debt (negative means net cash)−52−24−8−13−137
Net debt to EBITDA————−5.5x
Debt to equity1.3x———1.5x
Interest coverage−27.5x−12.0x−7.6x−10.0x3.9x
Current ratio1.0x1.4x1.2x1.4x1.6x
Quick ratio0.9x1.3x1.0x1.2x1.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Akebia Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $86,588 of Akebia Therapeutics shares on the open market, and 6 insiders sold $962,955, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jun 29, 2026Erik OstrowskiSVP, CFO, CBO & TreasurerSold plan56,019$1.11$62,181Form 4
Mar 4, 2026John P. ButlerCEO and President, DirectorBought69,270$1.25$86,588Form 4
Feb 2, 2026John P. ButlerCEO and President, DirectorSold plan341,305$1.39$474,414Form 4
Feb 2, 2026Nicholas GrundChief Commercial OfficerSold plan84,829$1.39$117,912Form 4
Feb 2, 2026Carolyn M. RucciSVP, Chief Legal OfficerSold plan69,772$1.39$96,983Form 4
Feb 2, 2026Steven Keith BurkeSVP, Chief Medical OfficerSold plan67,658$1.39$94,045Form 4
Feb 2, 2026Richard C MalabreSVP, Chief Accounting OfficerSold plan49,524$1.39$68,838Form 4
Feb 2, 2026Erik OstrowskiSVP, CFO, CBO & TreasurerSold plan34,951$1.39$48,582Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 93 of 97 of 9
Rule of 40−45.5%−43.1%76.1%
Altman Z''−22.61−25.54−12.49
Accruals ratio−9.6%−12.4%−24.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassFailPass
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin roseFailFailPass
Revenue rose relative to assetsFailPassPass
F-score3 of 93 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Akebia Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Akebia TherapeuticsFY2547.5%9.9%28.7%—−5.5x7
Puma BiotechnologyFY25−0.9%16.3%18.3%48.2%−1.4x8Compare
IDEAYA BiosciencesFY253,024.4%−72.8%−33.6%———Compare
Vanda PharmaceuticalsFY258.7%−70.0%−51.1%———Compare
AmarinFY25−6.5%−23.5%————Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue2181208335295212292195160236
Revenue growth—11,706.3%14.6%61.3%−12.1%−28.2%38.2%−33.5%−17.7%47.5%
Gross profit——200190−26120712097197
Research and development116231291323218148130633862
Operating income−136−77−178−286−378−264−81−46−5024
Net income−136−74−144−280−385−282−94−52−69−5
Diluted EPS (US$)−3.60−1.69−2.47−2.36−2.78−1.70−0.52−0.28−0.33−0.02
Diluted shares (millions)384458118138166183188211257
Cash flow
Cash from operations58−56−98−257−110−253−73−23−4168
Capital expenditure3227000000
Free cash flow55−58−99−264−111−253−73−23−4168
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation6919122423189811
Balance sheet at fiscal year end
Cash and short-term investments260318322148269150904352185
Debt incl. finance leases———76969866353948
Total assets300364996771644529356242221377
Total liabilities232242361376396455351272270344
Shareholders' equity68123636393244745−31−4933
Margins and ratios
Gross margin——96.3%56.6%−0.6%28.8%70.7%61.9%60.6%83.3%
Operating margin−8,889.9%−42.3%−85.8%−85.5%−128.2%−125.0%−27.6%−23.8%−31.5%9.9%
Net margin−8,843.5%−40.6%−69.1%−83.5%−130.6%−133.2%−32.2%−26.7%−43.3%−2.3%
Free cash flow margin3,599.0%−31.9%−47.7%−78.8%−37.6%−119.5%−25.1%−12.0%−25.4%28.7%
Rule of 40 (growth + FCF margin)—11,674.4%−33.1%−17.6%−49.6%−147.7%13.1%−45.5%−43.1%76.1%
Return on capital————−151.9%—————
Return on equity−136.3%−77.3%−37.9%−54.4%−120.8%−177.2%−237.8%———
Return on assets−61.3%−22.2%−21.1%−31.6%−54.4%−48.1%−21.3%−17.4%−30.0%−1.8%
Net debt to EBITDA—————————−5.5x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Akebia Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Akebia Therapeutics.